Rajib Biswas
CEO
C
CytoHub
8/10Traction
This company appears to be in a pre-launch or developmental phase, as indicated by the "Coming Soon" status. Further information about its specific industry focus or product offerings is not currently available on the provided page. The company name suggests a potential connection to biotechnology or cellular science.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$250KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
The development of effective therapies for heart failure is hindered by the limitations of traditional cardiotoxicity screening methods, which often fail to accurately predict drug responses in humans. Existing drug discovery processes lack physiologically relevant models for assessing drug efficacy and safety, leading to costly failures in later stages of development.
Solution
CytoHub offers an integrated biotechnology platform that leverages pluripotent stem cell-derived mini human hearts, called CardioVive™, to enhance drug discovery and regenerative medicine. CardioVive™ provides a reliable in-vitro model for cardiotoxicity screening, disease modeling, and drug efficacy testing. The company's BioEngineAI™ system uses artificial intelligence to analyze data from these models, enabling intelligent predictions and accelerating the development of novel therapeutics. CytoHub also provides services for process development, bioreactor scale-up, and analytical development to support cell therapy manufacturing.
Target Audience
CytoHub's primary customers are pharmaceutical companies, biotechnology firms, and research institutions involved in drug discovery, regenerative medicine, and cell therapy development.
Features
- CardioVive™: Pluripotent stem cell-derived mini human hearts for cardiotoxicity screening and drug discovery.
- BioEngineAI™: AI-driven system for intelligent predictions and development of novel therapeutics.
- iPSC-derived organoids and 3D cultures that replicate the structural and functional characteristics of human organs.
- Organoids-on-chip platforms to enable the study of drug responses, disease modeling, and toxicity screening in a controlled and highly reproducible manner.
- Analytical development services utilizing flow cytometry, omics, and cell-based assays.
- Capabilities for process development and bioreactor scale-up to optimize cell therapy manufacturing.
- Expertise in optimizing cultural protocols in adherent format and developing 3D suspension culture-based models.